- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Difelikefalin effective against pruritis in CKD patients
A new study published in Journal of the American Academy of Dermatology shows that oral difelikefalin effectively decreased moderate-to-severe pruritus in stage 3-5 chronic kidney disease (CKD) patients, recommending further research for this disease.
Patients with chronic renal disease must deal with the burden of persistent pruritus. Patients with NDD-CKD who experience pruritus can only use off-label medications as approved therapy.
Topical corticosteroids and antihistamines offer conflicting evidence, although gabapentinoids have been shown to be effective in clinical investigations with hemodialysis (HD) patients. Gil Yosipovitch and colleagues conducted this study to assess the effectiveness and safety of difelikefalin in decreasing itching in participants with non-dialysis-dependent CKD and those receiving hemodialysis.
Non-dialysis-dependent CKD (stages 3-5) and HD individuals with moderate-to-severe pruritus were included in this phase 2 randomized, double-blind, placebo-controlled dose-finding research. For 12 weeks, subjects were randomly assigned to either oral difelikefalin (0.25, 0.5, or 1.0 mg) or placebo. At week 12, the major end point was the change in the weekly mean Worst Itching Intensity Numeric Rating Scale (WI-NRS) score.
The key findings of this study were:
1. A total of 269 participants were randomly assigned (mean [SD] baseline WI-NRS: 7.1 [1.2]).
2. At week 12, difelikefalin 1.0 mg substantially reduced weekly mean WI-NRS scores compared to placebo (P =.018), with numerical reductions seen with difelikefalin 0.25 and 0.5 mg.
3. At week 12, 38.6% of participants on difelikefalin 1.0 mg had a full response (WI-NRS 0-1) compared to 14.4% on placebo. Difelikefalin improved itch-related quality-of-life indicators by 20%.
4. Dizziness, falls, constipation, diarrhoea, gastroesophageal reflux disease, tiredness, hyperkalemia, hypertension, and urinary tract infection were the most prevalent treatment-emergent side events.
Over a 12-week period, oral difelikefalin 1.0 mg effectively decreased itch in participants with moderate-to-severe pruritus related to stage 3-5 CKD. The findings of this phase 2 trial support the use of kappa opioid receptor activation to treat systemic itch associated with CKD prior to dialysis. These findings support additional investigation of this group, notably advanced CKD patients, as well as the advancement of oral difelikefalin in ongoing phase 3 studies.
Reference:
Yosipovitch, G., Awad, A., Spencer, R. H., Munera, C., & Menzaghi, F. (2023). A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus. In Journal of the American Academy of Dermatology. Elsevier BV. https://doi.org/10.1016/j.jaad.2023.03.051
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751